ARA-290
Cibinetide
ARA-290 (cibinetide) is an 11-amino-acid peptide engineered from erythropoietin to keep its tissue-protective signalling without stimulating red-blood-cell production, and it has been tested in randomised human trials.
Regulatory status: Not FDA-approved. It is an investigational drug that has completed published randomised clinical trials but is not a marketed product.
Default vial
10 mg
Default mix
2 mL
Reported range
2–4 mg
Draw (U-100)
80 u
Non-hematopoietic EPO peptide studied for small-fiber neuropathy; trial protocols ran 4 mg daily for 28 days.
What it is
- An 11-amino-acid peptide derived from a specific region of erythropoietin.
- Designed to engage the so-called innate repair receptor rather than the classical erythropoietin receptor, avoiding blood-production effects.
- Given by subcutaneous injection in the published human trials.
- Investigated in type 2 diabetes with neuropathic symptoms and other tissue-injury and inflammatory contexts.
How it is described to act
- 1
Administered subcutaneously to participants in the reported clinical trials.
- 2
Distributes systemically; trial reports describe effects on neural and metabolic measures relevant to diabetic neuropathy.
- 3
Pharmacology reviews propose action at a heteromeric innate repair receptor distinct from the classical EPO receptor, engaging anti-inflammatory and repair signalling.
- 4
Observed in randomised trials in people with type 2 diabetes and neuropathic symptoms.
What the research has looked at
Randomised trial in diabetic neuropathy
- A randomised trial published in Molecular Medicine (2015) reported that ARA 290 improved metabolic control and neuropathic symptoms in patients with type 2 diabetes. The trial was small, so the authors treat the result as preliminary.
Mechanistic review
- A 2015 review in Pharmacology & Therapeutics described long-lasting innate-repair-receptor-mediated effects of this non-erythropoietic EPO-derived peptide across tissue-injury models.
Strength of evidence: Limited human evidence
Unlike most compounds in this library, ARA-290 has published randomised human data — but sample sizes are small and it remains investigational rather than approved.
Some human data exist, but they are small, short, or not designed to answer the questions people ask online.
Reported cautions and unknowns
- The 2015 trial reports that the molecule was specifically designed to avoid the red-blood-cell-raising effects of native erythropoietin, which was an intended safety improvement.
- As an investigational compound, comprehensive long-term human safety data remain limited.
- Reported outcomes come from one patient population — type 2 diabetes with neuropathy — and generalisability to other groups is not established.
References
Handling this vial
- Lyophilized vials are generally stored at 2–8 °C and kept out of light; once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after 28 days.
- Mix by aiming water down the vial wall and rolling gently — do not shake — and never re-freeze a reconstituted vial.
- Pep-Tidy cannot verify what is in your vial. Ask your supplier for a current Certificate of Analysis (HPLC/MS).
ARA-290 questions people ask
How do you reconstitute ARA-290?
A common starting point for a 10 mg vial of ARA-290 is 2 mL of bacteriostatic water, which gives 5 mg per mL. Aim the water down the inside wall of the vial, let it dissolve on its own, and roll gently instead of shaking. Pep-Tidy's reconstitution calculator will recalculate the numbers for any other vial size or water volume you use.
How many units of ARA-290 is one dose?
At 5 mg per mL, that works out to about 80 units on a U-100 insulin syringe for a 4000 mcg dose. Change the vial size, water volume, or target dose in the calculator and the syringe reading updates with it. This is arithmetic, not a dosing recommendation.
What dosing schedule is reported for ARA-290?
Published and community sources describe 2–4 mg, subcutaneous, every day, typically run 4 weeks on and 4 weeks off. These figures describe what has been reported, not what anyone should take — talk to a licensed clinician first.
How should ARA-290 be stored?
Lyophilized ARA-290 vials are generally kept at 2–8 °C and out of light. Once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after about 28 days. Never re-freeze a reconstituted vial and never shake it.
Read this before you act on anything above
Everything on this page is a summary of what other people have published — it is not medical advice, not a recommendation, and not a dosing instruction. Reported dose ranges describe what appears in the literature or in community protocols, not what anyone should take. Talk to a licensed clinician before using any peptide.